Phaeochromocytoma: State-of-the-art

References

• Frankel F. Ein fall von doppelseitigem, völlig latent verhaufenen nebennierentumor und gleichzeitiger nephritis mit veränderungen am circulationapparat und retinitis. Arch Pathol Anat Physiol Klin Med, 1886, 103: 244–263.
   Google Scholar
• Neumann H. P. H., Vortmeyer A., Schmidt D., Wermer M., Erlic Z., Cascon A., et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med, 2007, 357: 1311–1315.
   Google Scholar
• Bravo E. L., Tagle R. Pheochromocytoma: State-of-the-Art and future prospects. Endocr Rev, 2003, 24: 539–553.
   Google Scholar
• Karagiannis A., Mikhailidis D. P., Athyros V. S., Harsoulis F. Pheochromocytoma: an update on genetics and management. Endocrine-Related Cancer, 2007, 14: 935–936.
   Google Scholar
• Young W. Endocrine hypertension. In: Williams Texbook of Endocrinology, 505–537. Saunders, Philadelphia, 2008.
   Google Scholar
• Adler J. T., Meyer-Rochon G. Y., Chen H., Benn D. E., Robinson B. G., Sippel R. S., Sidhu SB. Pheochromocytoma: current approaches and future directions. The Oncologist, 2008, 13: 779–793.
   Google Scholar
• Amar L., Gimenez-Roqueplo A. P., Hernigou A., Plouin J. P. Phéochromocytomes. In: Traité d’Endocrinologie 380–386. Médecine-Sciences. Flammarion, Paris, 2007.
   Google Scholar
• Mantero F., Terzolo M., Arnaldi G., Osella G., Masini A. M., Ali A. et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab, 2000, 85: 637–644.
   Google Scholar
• McNeil A. R., Blok B. H., Koelmeyer J. D., Burke M. P., Hilton J. M. Pheochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med, 2000, 30: 648–652.
   Google Scholar
• Bravo E. L., Gilford R. W. Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management. NEngl J Med, 1984, 311: 1298–1303.
   Google Scholar
• Neumann H. P., Bausch B., Mc Whinney S. R., Bender B. U., Gimm O., Franke G. et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med, 2002, 346: 1459–1466.
   Google Scholar
• Amar L., Bertherat J., Baudin E., Ajzenberg C., Bressac-de Paillerets B., Chabre O. et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol, 2005, 23: 88128818.
   Google Scholar
• Gimenez-Roqueplo A. P., Lehnery H., Mannelli M., Neumann H., Opocher G., Mahner E. R., Plouin J. P., on behalf of the European Network for the Study of Adrenal Tumours (ENS@T). Pheochromocytoma Working Group. Pheochromocytoma, new genes and screening strategies. Clin Endocrinol, 2006, 65: 699–705.
   Google Scholar
• Jimenez C., Cote G., Arnold A., Gagel RF. Should patients with apparent by sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes ? J Clin Endocrinol Metab, 2006, 91: 2851–2858.
   Google Scholar
• Baysal B. E., Ferrell R. E., Willett-Brozick J. E., Lawrence E. C., Myssiorek D., Bosch A. et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000, 287: 848–851.
   Google Scholar
• Donckier J. E. Endocrine diseases and diabetes. In: Textbook of Diabetes. 27.1–27.25. Blackwell Science, Oxford, 2003.
   Google Scholar
• Donckier J. E., Rosière A., Heureux F., Michel L. Diabetes Mellitus as a primary manifestation of multiple endocrine neoplasia type 2 B. Acta Chir Belg, 2008, 108: 732–737.
   Google Scholar
• Col V., de Cannière L., Messaoudi L., Michel L., Donckier J. Heart failure induced by pheochromocytoma: laparoscopic treatment and intraoperative changes of several new cardiovascular hormones. Horm Res, 1999, 51: 50–52.
   Google Scholar
• Donckier J. E., Delgrange E., Michel L. ECG abnormalities of endocrine origin. Heart, 2001, 85: 679.
   Google Scholar
• Sakel S. G., Manson J. E., Marawi S. T., Burokoff R. Watery diarrhoea syndrome due to an adrenal pheochromocytoma secreting vasoactive intestinal peptide. Dig Dis Sci, 1985, 30: 1201–1207.
   Google Scholar
• Mune T., Katakami H., Kato Y., Yasuda K., Matsukura S., Miura K. Production and secretion of parathyroid hormone-related protein in pheochromocytoma: participation of an a-adrenergic mechanism. J Clin Endocrinol Metab, 1993, 76: 757–762.
   Google Scholar
• Hes F. J., Hoppener J. W. M., Lipas C. J. M. Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab, 2003, 88: 969–974.
   Google Scholar
• Lenders J. W. M., Pacak K., Walther M. M., Lineham W. M., Mannelli M., Friber G. P. et al. Biochemical diagnosis of pheochromocytoma: which test is best ? JAMA, 2002, 287: 14271434.
   Google Scholar
• Sawka A. M., Jaeschker R., Singh R. J., Young W. F. Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab, 2003, 88: 553–558.
   Google Scholar
• Canale M. P., Bravo E. L. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab, 1994, 78: 1139–1144.
   Google Scholar
• Grossrubatscher E., Dalino P., Vignati F., Gambacorta M., Pugliese R., Boniardi M. et al. The role of chromogranin-A in the management of patients with pheochromocytoma. Clin Endocrinol, 2006, 65: 287–293.
   Google Scholar
• Rao F., Keiser H. R., O’Connor D. T. Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. Ann NY Acad Sci, 2002, 97: 530–532.
   Google Scholar
• van der Harst E., de Herder W. W., de Krugger R. R., Bruining H. A., Bonjer H. J., Lamberts S. W. et al. The value of plasma markers for the clinical behaviour of pheochromocytomas. Eur J Endocrinol, 2002, 147: 85–94.
   Google Scholar
• Donckier J., Michel L., Collard E., Berbinschi A., Ketelslegers J. M., Harvengt C. Parallel changes of atrial natriuretic factor and catecholamines during surgery for pheochro-mocytoma. Am J Med, 1988, 85: 278–279.
   Google Scholar
• Mouri T., Sone M., Takahashi K., Itoi K., Totsune K., Hayashi Y. Neuropeptide Y as a plasma marker for pheochromocytoma, gan-glioneuroblastoma and neuroblastoma. Clin Sci, 1992, 83: 205–211.
   Google Scholar
• Eisenhofer G., Goldstein D. S., Walther M. M., Friberg P., Lenders J. W. M., Keiser H. R. et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true-from false-positive test results. J Clin Endocrinol Metab, 2003, 88: 2656–2666.
   Google Scholar
• van der Harst E., de Herder W. W., Bruining H. A., Bonjer H. J., de Krijger R. R., Lamberts S. W. et al. [123I] Metaiodobenzyl-guanidine and [111 In] octreotide uptake in benign and malignant pheochromocytoma. J Clin Endocrinol Metab, 2001, 86: 685–693.
   Google Scholar
• Newbould E. C., Ross G. A., Dacie J. E., Bouloux P. M., Besser G. M., Grossman A. The use of venous catheterization in the diagnosis and localisation of bilateral pheochromocytomas. Clin Endocrinol, 1991, 35: 55–59.
   Google Scholar
• Prys-Roberts C. Phaeochromocytoma-recent progress in its management. Br J Anaesth, 2000, 85: 44–57.
   Google Scholar
• James M. F. M. Use of magnesium sulphate in the anaesthetic management of phaeochromocytoma: a review of 17 anaesthetics. Br J Anaesth, 1989, 62: 616–623.
   Google Scholar
• James M. F., Cronje L. Pheochromocytoma crisis: the use of magnesium sulphate. Anesth Analg, 2004, 99: 680–686.
   Google Scholar
• Gagner M., Lacroix A., Bolté E. Laparoscopic adrenalectomy in Cushing’s syndrome and pheochromocytoma. N Engl J Med, 1992, 327: 1033.
   Google Scholar
• Col V., de Cannière L., Collard E., Michel L., Donckier J. Laparoscopic adrenalectomy for phaeochromocytoma: endocrino-logical and surgical aspects of a new therapeutic approach. Clin Endocrinol, 1999, 50: 121–125.
   Google Scholar
• Michel L. A., Donckier J. E. Importance of secretion pattern in minimally invasive surgery for phaeochromocytoma. Clin Endocrinol, 2006, 66: 455–456.
   Google Scholar
• Michel L. A., de Cannière L., Hamoir E., Hubens G., Meurisse M., Squifflet J. P. Asymptomatic adrenal tumours: criteria for endoscopic removal. Eur J Surg, 1999, 165: 767–771.
   Google Scholar
• Salmenkivi K., Arola J., Voutailainen R., Ilvesmaki V., Haglund C., Kahri A. I. et al. Inhibin/activin betaB-subunit expression in phaeochromocytoma favors benign diagnosis. J Clin Endocrinol Metab, 2001, 86: 2231–2235.
   Google Scholar
• Helman L. J., Cohen P. S., Averbuch S. D., Cooper M. J., Keiser H. R., Israel M. A. Neuropeptide Y expression distinguishes malignant from benign phaeochromocytoma. J Clin Oncol, 1989, 7: 1720–1725.
   Google Scholar
• Loh K. C., Fitzgerald P. A., Mattay K. K., Yeo P. P., Price D. C. The treatment of malignant phaeochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest, 1997, 20: 648–658.
   Google Scholar
• Kaltsas G. A., Papadogias D., Makras P., Grossman A. B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer, 2005, 12: 683–699.
   Google Scholar
• Averbuch S. D., Steakley C. S., Young R. C., Gelmann E. P., Goldstein D. S., Stull R., Keiser H. R. Malignant phaeochromo-cytoma: effective treatment with a combination of cyclophos-phamide, vincristine and dacarbazine. Ann Intern Med, 1988, 109: 267–277.
   Google Scholar
• Sisson J. C., Shapiro B., Shulkin B. L. et al. Treatment of malignant pheochromocytomas with 131–1 metabenzylguanidine and chemotherapy. Am J Clin Oncol, 1999, 22: 364–370.
   Google Scholar
• Sausville E. A., Tomaszewski J. E., Ivy P. Clinical development of 17-allylamino,17-demethoxygeldanamycin. Curr Cancer Drug Targets, 2003, 3: 377–383.
   Google Scholar
• Manelli M. Management and treatment of phaeochromocytomas and paragangliomas. Ann NY Acad Sci, 2006, 1073: 405–416.
   Google Scholar
• Manelli M., Bemporad D. Diagnosis and management of phaeochromocytoma during pregnancy. J Endocrinol Invest, 2002, 25: 567–571.
   Google Scholar
• Wattanachanya L., Bunworasate U., Plengpanich W., Houngngam N., Buranasupkajom P., Sunthormyothin S. et al. Bilateral pheochromocytoma during the postpartum period. Arch Gynecol Obstet, 2009, 280 :1055–1058.
   Google Scholar
• Kim J., Reutrakul S., Davis D. B., Kaplan E. L., Refetoff S. Multiple endocrine neoplasia 2A presenting as peripartum cardio-myopathy due to catecholamine excess. Eur J Endocrinol, 2004, 151: 771–777.
   Google Scholar
• Frayssinet C., Vezzosi D., Huyghe E., Lorenzini F., Bennet A., Caron P. Retroperitoneal laparoscopic adrenalectomy in a pregnant woman presenting MEN 2A with a phaeochromocytoma: case report and review of the literature. Ann Endocrinol (Paris), 2008, 69: 53–57.
   Google Scholar
• Stenstrom G., Swolin K. Pheochromocytoma in pregnancy. Experience of treatment with phenoxybenzamine in three patients. Acta Obstet Gynecol Scand, 1985, 64: 357–361.
   Google Scholar
• Brandi M. L., Gagel R. F., Angeli A., Bilezikian J. P., Peck-Peccoz P., Bordi C. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab, 2001, 86: 56585671.
   Google Scholar
• Lips C. J. M. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on multiple endocrine neoplasia and von Hippel-Lindau disease. J Intern Med, 1998, 243: 589–594.
   Google Scholar
• Huang S. M., Tao B. L., Tzeng C. C., Liu H. T., Wang W. P. Prenatal molecular diagnosis of RET protooncogene mutation in multiple endocrine neoplasia type 2A. J Formos Med Assoc, 1997, 96: 542–544.
   Google Scholar